Total raised
$198.7M
Last: PIPE 2025-09
Stage
Public
Founded
2000
Headcount
121
HQ
Yavne
Sector
Health Tech & Life Sciences
About
MediWound is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.
Funding history · 6 rounds · $198.7M total
2025-09
PIPE
$30.0M
2024-07
PIPE
$6.7M
2023-02
PIPE
$8.0M
2022-10
PIPE
$30.0M
2022-02
PIPE
$9.0M
2013-06
Undisclosed
$18.0M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did MediWound become a public company and on which exchange?
- MediWound became public on NASDAQ in March 2014.
- What is MediWound's primary product and its indication?
- MediWound's primary product is NexoBrid, an FDA-approved biologic for the enzymatic removal of eschar in thermal burns.
- In which geographic markets is MediWound's NexoBrid currently marketed?
- NexoBrid is marketed in the United States, European Union, Japan, and additional international markets.
- What is MediWound's late-stage pipeline product and its intended use?
- MediWound's late-stage pipeline product is EscharEx, an investigational therapy for the debridement of chronic wounds.
- What was a significant funding event for MediWound in February 2023?
- In February 2023, MediWound announced the closing of a $27.5 million registered direct offering of ordinary shares, with lead investor Steve Cohen.
- What was a key regulatory approval for NexoBrid in January 2024?
- In January 2024, the FDA accepted for review a supplement to the NexoBrid Biologics License Application (BLA) to include pediatric patients with severe thermal burns.
- What strategic collaboration did MediWound announce in October 2023 for its EscharEx product?
- In October 2023, MediWound announced a collaboration with 3M on the EscharEx Phase III study.
- What was the outcome of MediWound's U.S. Phase I/II study of MW005 in July 2023?
- In July 2023, MediWound announced positive results in its U.S. Phase I/II study of MW005 for the treatment of Basal Cell Carcinoma.
- What was a notable funding event for MediWound in July 2024?
- In July 2024, MediWound announced a $25 million strategic private placement financing, with Mölnlycke Health Care as a lead investor.
- What was a significant development regarding NexoBrid's pediatric use in August 2024?
- In August 2024, MediWound announced U.S. Food and Drug Administration approval of NexoBrid for the treatment of pediatric patients with severe thermal burns.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B2C
Highlights
1 Patents
Tags
tissue-regenerationdermatologyburnsbiotechnologytopical-treatmentpatientspharma-companiespharmaceuticals